Combination intravitreous melphalan and bevacizumb for cutaneous metastatic melanoma to the vitreous and retina Journal Article

   


Authors: Francis, J. H.; Canestraro, J.; Abramson, D. H.; Barker, C. A.; Shoushtari, A. N.
Article Title: Combination intravitreous melphalan and bevacizumb for cutaneous metastatic melanoma to the vitreous and retina
Abstract: Purpose: Cutaneous melanoma metastatic to the vitreous/retina is rare but increasingly common. Due to the potential of recurrent disease with current treatment options and the propensity for these eyes to develop neovascularization, these eyes can pose a treatment challenge and novel management strategies are needed. This case series explores the use of combination, sequential intravitreous melphalan and bevacizumab. Observation: Two eyes of two patients with cutaneous melanoma metastatic to the vitreoretina were eye treated with combination intravitreous melphalan (10-30 mcg) and bevacizumab (1.25 mg) given sequentially during the same office visit, at monthly intervals. Both cases had control of disease at 7- and 12-months follow up. Furthermore, treatment reversed neovascular glaucoma and dramatically improved vision in the eye of one patient; and stabilized vision without the development of neovascularization in the eye of the other patient. There were no ocular adverse events noted in either eye. Conclusions and Importance: Combination, sequential intravitreous melphalan and bevacizumab is well-tolerated and an attractive approach for treating eyes with intraocular metastatic melanoma. © 2022
Keywords: bevacizumab; melphalan; retina; neovascularization; metastatic melanoma; vitreous
Journal Title: American Journal of Ophthalmology Case Reports
Volume: 26
ISSN: 2451-9936
Publisher: Elsevier Inc.  
Date Published: 2022-06-01
Start Page: 101519
Language: English
DOI: 10.1016/j.ajoc.2022.101519
PROVIDER: scopus
PMCID: PMC9020100
PUBMED: 35464680
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85127770385&doi=10.1016%2fj.ajoc.2022.101519&partnerID=40&md5=cdfc915ac816a28a7d700f5ff30804ef
Notes: Article -- Export Date: 2 May 2022 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Jasmine Helen Francis
    256 Francis
  2. David H Abramson
    389 Abramson
  3. Christopher Barker
    218 Barker
  4. Alexander Noor Shoushtari
    244 Shoushtari
  5. Julia Canestraro
    27 Canestraro
Related MSK Work